# Procedural Advantages of a Novel Drug-Eluting Coronary Stent

Study · id `cardio:ct-nct02881216` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02881216](<https://clinicaltrials.gov/study/NCT02881216>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02881216

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 814 participants.

## Technical summary

Registry record NCT02881216. Non-randomized; no masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 814 participants (enrolled count; ClinicalTrials.gov record NCT02881216, source copy `cardio:ctgov-nct02881216-2016-08-29`, retrieved 2026-10-26)
- Start date: 2015-01 (registry gives no type) (ClinicalTrials.gov record NCT02881216, source copy `cardio:ctgov-nct02881216-2016-08-29`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02881216, source copy `cardio:ctgov-nct02881216-2016-08-29`, retrieved 2026-10-26)
- Completion: 2016-06 (actual) (ClinicalTrials.gov record NCT02881216, source copy `cardio:ctgov-nct02881216-2016-08-29`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02881216-2016-08-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Procedural Advantages of a Novel Drug-Eluting Coronary Stent
- Condition: Coronary Artery Disease
- Intervention (Device): Synergy Stent
- Intervention (Device): Currently common drug-eluting stent (DES)
- Lead sponsor: University Hospital Heidelberg
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: University Hospital Heidelberg (`cardio:org-university-hospital-heidelberg`)

## Provenance

Content hash: 083c66228c45dd0b331253a89f71874db88ed55c1b5772ad0ec6f97e806b13bc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
